A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose: Nintedanib enhances the activity of chemotherapy in metastatic non–small cell lung cancer (NSCLC). In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. Patients and Methods: Eligible patients had stage IB (≥4 cm)–IIIA resectable NSCLC. A safety run-in phase was followed by an expansion phase with nintedanib 200 mg orally twice a day (28 days), followed by three cycles of cisplatin (75 mg/m2), docetaxel (75 mg/m2) every 21 days plus nintedanib, followed by surgery. With 33 planned patients, the study had 90% power to detect an MPR increase from 15% to 35%. Results: Twenty-one patients (stages I/II/III, N = 1/8/12) were treated. One of 15 patients treated with nintedanib 200 mg achieved MPR [7%, 95% confidence interval (CI), 0.2%–32%]. Best ORR in 20 evaluable patients was 30% (6/20, 95% CI, 12%–54%). Twelve-month recurrence-free survival and overall survival were 66% (95% CI, 47%–93%) and 91% (95% CI, 79%–100%), respectively. Most frequent treatment-related grade 3–4 toxicities were transaminitis and electrolyte abnormalities. On the basis of an interim analysis the study was discontinued for futility. Higher levels of CD3+ and cytotoxic CD3+CD8+ T cells were found in treated tumors of patients who were alive than in those who died (652.8 vs. 213.4 cells/mm2, P = 0.048; 142.3 vs. 35.6 cells/mm2, P = 0.018). Conclusions: Although tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies. See related commentary by Blakely and McCoach, p. 3499
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We have previously shown that the histopathologic response to neoadjuvant chemotherapy is a stronger predictor of improved survival outcome, compared with responses at CT13,25.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [13]
In the citing paper
“Historically, neoadjuvant chemotherapy has resulted in MPR rates between 7% and 27% in localized NSCLC4,6,7,12,13.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“RFS and OS were estimated using the Kaplan– Meier (KM)method (23).”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · cited 1×
“005) based on a meta-analysis of 4,584 patients (2).”
MethodNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · cited 1×
“In the first reported study 477 of 21 patients (stage IB-IIIA) treated with two doses of nivolumab followed by surgery, authors 478 observed a MPR of 45% (9/20) with a radiographic response rate of only 10% (2/21) (29).”
BackgroundSelf-citationPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675 · cited 2×
“Nintedanib may 124 prime the tumor vasculature for enhanced delivery of chemotherapy, by inhibiting VEGFR, 125 FGFR and PDGFR in the endothelium, pericytes and smooth muscle cells (14), and possibly 126 normalizing the distorted architecture of tumor microvessels (15, 16).”
BackgroundBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 2×
“The priming phase of 440 neoadjuvant nintedanib alone tested whether tumors would decrease in size via inhibition of 441 receptor tyrosine kinases, degradation of tumor vessels and subsequent tumor necrosis (14), or 442 via direct antitumor activity (17).”
BackgroundMethodReck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951 · cited 1×
“It has been approved in the European Union in combination with docetaxel for advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy based on progression-free survival (PFS) improvements over docetaxel alone, and OS improvements in the adenocarcinoma histology populat…”
BackgroundHellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Self-citation
Cited by
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Self-citationEvolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Self-citationNederlof, I., Isaeva, O. I., de Graaf, M., Gielen, R., Bakker, N. A. M., Rolfes, A. L., Garner, H., Boeckx, B., Traets, J. J. H., Mandjes, I. A. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03249-3 · Cited by 94
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 70
Godoy, L. A., Chen, J., Ma, W., Lally, J., Toomey, K. A., Rajappa, P., Sheridan, R., Mahajan, S., Stollenwerk, N. S., Phan, C. T., et al. (2023) · Biomarker Research · doi:10.1186/s40364-022-00444-7 · Cited by 74
Metadata
- Authors
- Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., Lam, V. K., Lu, C., Mott, F. E., Simon, G. R., Antonoff, M. B., Mehran, R. J., Rice, D. C., Behrens, C., Weissferdt, A., Moran, C., Vaporciyan, A. A., Lee, J. J., Swisher, S. G., Gibbons, D. L., Wistuba, I. I., William, W. N., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- 4Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- William, William N.
- Heymach, John V.
- ORCID
- Cascone, Tina
- Sepesi, Boris
- Lin, Heather Y.
- Kalhor, Neda
- Parra, Edwin R.
- Jiang, Mei
- Zhang, Jianjun
- Tsao, Anne S.
- Lam, Vincent K.
- Lu, Charles
- Mott, Frank E.
- Simon, George R.
- Antonoff, Mara B.
- Mehran, Reza J.
- Rice, David C.
- Behrens, Carmen
- Weissferdt, Annikka
- Vaporciyan, Ara A.
- Swisher, Stephen G.
- Gibbons, Don L.
- Wistuba, Ignacio I.
- William, William N.
- Heymach, John V.
- Venue
- Clinical Cancer Research
- Published
- 2020-07-15
- Volume
- 26
- Issue
- 14
- Pages
- 3525-3536
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC7446232
- OpenAlex
- W3011014692
- Cited by
- 31
- References
- 35
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Boehringer Ingelheim
- Lung SPORE grant 5 (P50 CA070907)
- Cancer Center Support Grant (P30 CA016672)
- American Society of Clinical Oncology (12895)
- The University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program
- The University of Texas MD Anderson Cancer Center CG Johnson Foundation Advanced Scholar Program
- The University of Texas MD Anderson Cancer Center Khalifa Scholar Program
- The University of Texas MD Anderson Cancer Center Physician Scientist Program
- T.J. Martell Foundation
- Bruton Endowed Chair in Tumor Biology Funds
- The Bob Mayberry Foundation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- nintedanib, non-small cell lung cancer, neoadjuvant chemotherapy, cisplatin, docetaxel, resectable lung cancer, major pathological response, tumor-infiltrating lymphocytes, CD8+ T cells, treatment toxicity, futility, recurrence-free survival, overall survival, tyrosine kinase inhibitor combination therapy, immunotherapy biomarkers, elevated liver enzymes
- MeSH terms
- Docetaxel, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Humans, Indoles, Lung Neoplasms, Neoplasm Staging, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-4180
- The paper
- Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., Lam, V. K., Lu, C., Mott, F. E., Simon, G. R., Antonoff, M. B., Mehran, R. J., Rice, D. C., Behrens, C., Weissferdt, A., . . . Heymach, J. V. (2020). A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-4180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.